Amitiza TPP — Settlement Summary

Last Modified on 09/22/2026 2:01 pm EDT

Amitiza Antitrust Litigation – Third-Party Payor (TPP) Class Action

Summary

This class action lawsuit, *In re Amitiza Antitrust Litigation*, Master File No. 21-cv-11057 (D. Mass.), alleges that Takeda and other defendants engaged in an anticompetitive scheme — including an unlawful reverse payment — to delay generic competition for the prescription drug Amitiza (lubiprostone) by up to five years. As a result, third-party payors (TPPs) allegedly paid artificially inflated prices for Amitiza and its AB-rated generic equivalents. No settlement has been reached at this time; the case is currently proceeding as a certified class action.

Announcements

No settlement has been reached and no money is currently available. The settlement website notes explicitly: "At this time, no money is available, and there is no guarantee that any will become available in the future." The litigation is ongoing. The Court has certified the TPP Classes and appointed Premera Blue Cross as class representative. Class members who wish to opt out must do so by **April 10, 2026**.

Settlement Amount

Not yet available. No settlement has been reached. The case is proceeding toward trial. Plaintiff seeks damages in the form of overcharges allegedly caused by Defendants' anticompetitive conduct, plus attorneys' fees and litigation costs.

Class Period

Not yet available on the settlement website. The complaint alleges that Defendants' scheme delayed generic entry for **up to five years**, but the specific class period date range is not stated on the monitored page. Refer to the Long-Form Notice for the precise dates.

Filing Deadline

No claim filing deadline has been established because no settlement has been reached. The only current deadline is the **opt-out (exclusion) deadline of April 10, 2026**. FRS should monitor this case for any future settlement announcement and associated claim filing deadline.

Who Qualifies

The class consists of **third-party payors (TPPs)** — such as health insurers, health plans, self-funded employee benefit plans, and similar entities — that purchased or paid for some or all of the purchase price of:

- Brand-name **Amitiza (lubiprostone)**, and/or
- **AB-rated generic versions of Amitiza (lubiprostone)**

during the relevant class period. The exact class definition is contained in the Long-Form Notice available on the

settlement website.

Who Is Excluded

Specific exclusions are not detailed on the monitored page. Standard class action exclusions (e.g., defendants and their affiliates, government entities, judges) likely apply. Refer to the Long-Form Notice for the complete list of excluded parties. Additionally, any TPP that submits a valid and timely request for exclusion by **April 10, 2026** will be excluded from the Classes.

How to File

No claim form is currently available because no settlement has been reached. At this stage, class members have the following options:

- **Do Nothing:** Remain in the class and be bound by any future court decision or settlement. You will be entitled to share in any recovery if one becomes available, but you give up your right to sue defendants separately over the same claims.
- **Exclude Yourself (Opt Out):** Submit a written exclusion request by **April 10, 2026**. This is the only option that preserves your right to file your own lawsuit against defendants. Instructions are included in the Long-Form Notice, available for download at the settlement website. Exclusion requests should follow the specific instructions in the Notice.
- **Get More Information:** Review the Long-Form Notice and contact Class Counsel (see Contact Information page on the settlement website) with any questions. Do not contact the Court or Defendants directly.

FRS should monitor the case for a future settlement announcement, at which point a claim filing process and deadline will be established.

Defendants

- **Takeda Pharmaceuticals** — Manufacturer and marketer of brand-name Amitiza (lubiprostone). Allegedly orchestrated an anticompetitive scheme, including the payment of an unlawful reverse payment, to delay generic competition for up to five years.
- **Additional Defendants** — Not individually named on the monitored page. Refer to the Long-Form Notice and Court Documents tab on the settlement website for the full list of named defendants.

All defendants deny the allegations and deny that plaintiff or class members are entitled to damages or other relief.

Case History

- **2021:** Complaint filed; action assigned Master File No. 21-cv-11057 in the U.S. District Court for the District of Massachusetts.
- **Date not specified:** Court certifies TPP Classes and appoints Premera Blue Cross as class representative.
- **Date not specified:** Notice Administrator appointed; official litigation website established to notify class members.
- **April 10, 2026:** Deadline for class members to exclude themselves from the Classes.
- **Ongoing:** Litigation continues; no settlement has been reached as of the date of this article.

Source

Settlement website (Home Page): **https://www.amitzatpplitigation.com** (exact URL inferred from site content — verify against the actual monitored URL).

Additional information available under the Court Documents, FAQs, and Contact Information tabs on the same site.

Long-Form Notice available for download directly from the settlement website.

Last Updated

2025-09-22

Reviewer Flags

- **First draft** — No prior version exists in the knowledge base.
- **Source:** All information derived solely from the Amitiza TPP Home Page (one monitored page). No additional pages (FAQs, Court Documents, Contact Information) were provided for synthesis.
- **Potential contradiction / flag:** The website is styled as a "settlement website" and this article is filed under that category, but the page explicitly states *"no money is currently available"* and no settlement has been reached. This is a **class certification / litigation notice site**, not a settlement claims site. FRS staff should be aware that no claims can be filed at this time and should monitor for a future settlement announcement.
- **Class period dates:** Not published on the monitored page. The only reference is that the delay lasted "up to five years." Reviewer should pull the Long-Form Notice to obtain exact class period start and end dates and update this article accordingly.
- **Defendant list:** Only Takeda is named explicitly on the monitored page. Additional defendants are referenced but not identified. Reviewer should check the Court Documents tab or Long-Form Notice and update the Defendants section.
- **Opt-out deadline (April 10, 2026):** This is the most time-sensitive item for FRS clients who may wish to preserve independent litigation rights. Flag for immediate client outreach if applicable.
- **Settlement website URL:** The exact URL was not included in the raw page content provided. Reviewer should confirm and update the Source field with the verified URL.
- **"Last Updated" date:** The task instructions specify today's date as 2026-09-22, but the opt-out deadline is April 10, 2026 — which would already be in the past if today is September 2026. This internal contradiction should be reviewed: if the opt-out deadline has already passed, the Announcements and How to File sections should be updated accordingly.